# An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

> **NCT01646125** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 59 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** AUY922
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT01646125
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11-23
- **Primary completion:** 2015-11-04
- **Final completion:** 2015-11-04
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01646125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01646125, "An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01646125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*